Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Clinical trial NCT05382936 · TERMINATED
Trial details
- NCT number
- NCT05382936
- Sponsor
- Stemline Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-19
- Primary completion
- 2023-05-05
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.